The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus

Laboratory for Clinical Investigation, Osaka University Hospital, Suita, Osaka 565-0871, Japan. nojima@hplab.med.osaka-u.ac.jp

In an effort to clarify the clinical significance of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA), we examined the prevalence of anti-cardiolipin antibodies (aCL), anti-beta2-glycoprotein I antibodies (anti-beta2-GPI), antiprothrombin antibodies (anti-PT), and anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) in 175 patients with systemic lupus erythematosus (SLE) comprising 67 patients with thrombotic complications. The present study showed that positive results of anti-beta2-GPI-ELISA and anti-PS/PT-ELISA could serve as markers of thrombotic complications in patients with SLE, whereas aCL and anti-PT are less reliable as markers of these complications. Furthermore, results of the anti-PS/PT-ELISA correlate best with the occurrence of both arterial and venous thrombosis in patients with SLE.

This article has been cited by other articles:

				J. Nojima, Y. Masuda, Y. Iwatani, H. Kuratsune, Y. Watanabe, E. Suehisa, T. Takano, Y. Hidaka, and Y. Kanakura Arteriosclerosis obliterans associated with anti-cardiolipin antibody / {beta}2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus Rheumatology, May 1, 2008; 47(5): 684 - 689. [Abstract] [Full Text] [PDF]

				G. S. Hill and D. Nochy Antiphospholipid Syndrome in Systemic Lupus Erythematosus J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2461 - 2464. [Abstract] [Full Text] [PDF]